Allogene Therapeutics Loses 23% Year to Date: How to Play the Stock? [Yahoo! Finance]
Allogene Therapeutics, Inc. (ALLO)
Last allogene therapeutics, inc. earnings: 2/27 04:30 am
Check Earnings Report
Company Research
Source: Yahoo! Finance
The stock has also underperformed the sector and the S&P 500 during the same period, as shown in the chart below. ALLO's shares are trading below the 50 and 200-day moving averages. Image Source: Zacks Investment Research The decline in stock price can be attributed to the strategic changes in Allogene's pipeline, announced at the start of this year. This delayed management's plans to bring cema-cel, its lead pipeline drug, to the market by at least a couple of years. Let's dig into the stock's prospects. In January, management announced a major strategic update to its pipeline when it decided to upgrade cema-cel from being a third-line therapy in large B cell lymphoma (LBCL) patients to a frontline therapy. Based on this pivot, Allogene started the phase II ALPHA3 study in June, evaluating cema-cel as a potential first-line treatment for newly diagnosed and treated LBCL patients who are likely to relapse and need further therapy. Management intends to administer the therapy
Show less
Read more
Impact Snapshot
Event Time:
ALLO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ALLO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ALLO alerts
High impacting Allogene Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
ALLO
News
- Allogene Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceGlobeNewswire
- Allogene Therapeutics Acknowledges the Passing of Founding Board Member David Bonderman [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics Acknowledges the Passing of Founding Board Member David BondermanGlobeNewswire
- Allogeneic T Cell Therapies Market Report, 2024-2028 & 2033 - Valued at $1.16 Billion in 2024, the Industry is Forecast to Generate Revenues of $1.69 Billion by 2028 [Yahoo! Finance]Yahoo! Finance
- Allogene Therapeutics Announces Participation in December Investor ConferencesGlobeNewswire
ALLO
Earnings
- 11/7/24 - Beat
ALLO
Sec Filings
- 12/10/24 - Form 4
- 12/9/24 - Form 4
- 12/9/24 - Form 144
- ALLO's page on the SEC website